| Pancreatic cancer JD Mizrahi, R Surana, JW Valle, RT Shroff The Lancet 395 (10242), 2008-2020, 2020 | 2258 | 2020 |
| Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study GK Abou-Alfa, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ... The Lancet Oncology 21 (6), 796-807, 2020 | 966 | 2020 |
| Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma M Javle, M Lowery, RT Shroff, KH Weiss, C Springfeld, MJ Borad, ... Journal of Clinical Oncology 36 (3), 276-282, 2018 | 728 | 2018 |
| Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles F Farshidfar, S Zheng, MC Gingras, Y Newton, J Shih, AG Robertson, ... Cell reports 18 (11), 2780-2794, 2017 | 723 | 2017 |
| Integrated genomic characterization of pancreatic ductal adenocarcinoma BJ Raphael, RH Hruban, AJ Aguirre, RA Moffitt, JJ Yeh, C Stewart, ... Cancer cell 32 (2), 185-203. e13, 2017 | 687 | 2017 |
| Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline JD Gordan, EB Kennedy, GK Abou-Alfa, MS Beg, ST Brower, TP Gade, ... Journal of Clinical Oncology 38 (36), 4317-4345, 2020 | 512 | 2020 |
| Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications CR Churi, R Shroff, Y Wang, A Rashid, HSC Kang, J Weatherly, M Zuo, ... PloS one 9 (12), e115383, 2014 | 481 | 2014 |
| Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial RT Shroff, MM Javle, L Xiao, AO Kaseb, GR Varadhachary, RA Wolff, ... JAMA oncology 5 (6), 824-830, 2019 | 457 | 2019 |
| Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline RT Shroff, EB Kennedy, M Bachini, T Bekaii-Saab, C Crane, J Edeline, ... Journal of Clinical Oncology 37 (12), 1015-1027, 2019 | 427 | 2019 |
| Biliary cancer: utility of next‐generation sequencing for clinical management M Javle, T Bekaii‐Saab, A Jain, Y Wang, RK Kelley, K Wang, HC Kang, ... Cancer 122 (24), 3838-3847, 2016 | 415 | 2016 |
| Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial AX Zhu, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ... JAMA oncology 7 (11), 1669-1677, 2021 | 390 | 2021 |
| Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis R Tao, S Krishnan, PR Bhosale, MM Javle, TA Aloia, RT Shroff, AO Kaseb, ... Journal of Clinical Oncology 34 (3), 219-226, 2016 | 311 | 2016 |
| HER2/neu-directed therapy for biliary tract cancer M Javle, C Churi, HSC Kang, R Shroff, F Janku, R Surapaneni, M Zuo, ... Journal of hematology & oncology 8, 1-9, 2015 | 251 | 2015 |
| Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series KE Lunsford, M Javle, K Heyne, RT Shroff, R Abdel-Wahab, N Gupta, ... The lancet Gastroenterology & hepatology 3 (5), 337-348, 2018 | 241 | 2018 |
| Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study MA Lowery, HA Burris, F Janku, RT Shroff, JM Cleary, NS Azad, L Goyal, ... The lancet Gastroenterology & hepatology 4 (9), 711-720, 2019 | 230 | 2019 |
| Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial JM Llovet, M Kudo, P Merle, T Meyer, S Qin, M Ikeda, R Xu, J Edeline, ... The lancet oncology 24 (12), 1399-1410, 2023 | 214 | 2023 |
| Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors RT Shroff, P Chalasani, R Wei, D Pennington, G Quirk, MV Schoenle, ... Nature medicine 27 (11), 2002-2011, 2021 | 213 | 2021 |
| Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation RT Shroff, A Hendifar, RR McWilliams, R Geva, R Epelbaum, L Rolfe, ... JCO precision oncology 2, 1-15, 2018 | 213 | 2018 |
| AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma CL Bowlus, L Arrivé, A Bergquist, M Deneau, L Forman, SI Ilyas, ... Hepatology 77 (2), 659-702, 2023 | 195 | 2023 |
| Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies MM Javle, RT Shroff, H Xiong, GA Varadhachary, D Fogelman, SA Reddy, ... BMC cancer 10, 1-7, 2010 | 192 | 2010 |
